Keeping Up With “The Energizer Bunny”: US FDA Commissioner Gottlieb As A Boss
Three center directors agree that Gottlieb’s facility for public communications is a boon for FDA – and that the commissioner is appropriately hands-off when it comes to day-to-day decisions on scientific or policy issues.
You may also be interested in...
Acting commissioner is entering the usual learning curve for new leaders of the agency. It’s a reminder of how unusual it was to skip that step under his predecessor.
Amid all the praise for his raising of FDA's profile and aggressive policy stances, Scott Gottlieb's most valuable contribution while in office may have been leaving the agency fundamentally unchanged, an important lesson for incoming Acting Commissioner Norman Sharpless.
Drug pricing hearings likely will involve FDA, but most pressing issue facing agency following midterms may be whether Commissioner Gottlieb will depart.